Last reviewed · How we verify
vehicle of bimatoprost solution 0.03 %
vehicle of bimatoprost solution 0.03 % is a Prostaglandin analog Small molecule drug developed by Allergan. It is currently in Phase 3 development for Glaucoma, Ocular hypertension.
Bimatoprost is a prostaglandin analog that mimics the action of prostaglandin F2-alpha, leading to increased uveoscleral outflow and decreased intraocular pressure.
Bimatoprost is a prostaglandin analog that mimics the action of prostaglandin F2-alpha, leading to increased uveoscleral outflow and decreased intraocular pressure. Used for Glaucoma, Ocular hypertension.
At a glance
| Generic name | vehicle of bimatoprost solution 0.03 % |
|---|---|
| Sponsor | Allergan |
| Drug class | Prostaglandin analog |
| Target | Prostaglandin F2-alpha receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Bimatoprost works by binding to the prostaglandin F2-alpha receptor, which leads to the relaxation of the uveoscleral tissue and increased outflow of aqueous humor from the eye. This results in a decrease in intraocular pressure, making it an effective treatment for glaucoma and ocular hypertension.
Approved indications
- Glaucoma
- Ocular hypertension
Common side effects
- Eyelid skin darkening
- Itching
- Redness of the eye
- Dry eye
- Headache
- Eye pain
- Blepharitis
- Conjunctivitis
- Uveitis
- Iritis
Key clinical trials
- Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis (PHASE3)
- Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis (PHASE3)
- Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension (NA)
- Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children (PHASE4)
- Bimatoprost in the Treatment of Eyelash Hypotrichosis (PHASE3)
- Topical Bimatoprost Effect on Androgen Dependent Hair Follicles (PHASE2)
- Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension (PHASE2)
- Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- vehicle of bimatoprost solution 0.03 % CI brief — competitive landscape report
- vehicle of bimatoprost solution 0.03 % updates RSS · CI watch RSS
- Allergan portfolio CI
Frequently asked questions about vehicle of bimatoprost solution 0.03 %
What is vehicle of bimatoprost solution 0.03 %?
How does vehicle of bimatoprost solution 0.03 % work?
What is vehicle of bimatoprost solution 0.03 % used for?
Who makes vehicle of bimatoprost solution 0.03 %?
What drug class is vehicle of bimatoprost solution 0.03 % in?
What development phase is vehicle of bimatoprost solution 0.03 % in?
What are the side effects of vehicle of bimatoprost solution 0.03 %?
What does vehicle of bimatoprost solution 0.03 % target?
Related
- Drug class: All Prostaglandin analog drugs
- Target: All drugs targeting Prostaglandin F2-alpha receptor
- Manufacturer: Allergan — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Glaucoma
- Indication: Drugs for Ocular hypertension
- Compare: vehicle of bimatoprost solution 0.03 % vs similar drugs
- Pricing: vehicle of bimatoprost solution 0.03 % cost, discount & access